AavantiBio, Aldevron partner on gene therapy

By The Science Advisory Board staff writers

July 21, 2021 -- Aldevron made a deal to supply plasmid DNA that will enable AavantiBio to advance its gene therapies for rare genetic diseases.

Aldevron will supply plasmids to AavantiBio's planned vector core and contract development manufacturing organization partners. Also, the partnership includes materials for proof-of-concept and good lab practices (GLP) toxicology studies for future programs.

Danaher to acquire Aldevron in deal valued at $9.6B
Danaher announced it has signed a deal to buy DNA and messenger RNA manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as...
Aldevron adds AAV plasmid product offerings
Aldevron has launched rep/cap plasmids to support adeno-associated virus (AAV) vector manufacturing.

Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter